SynthesisMedical mycology2024
Cryptococcosis-a systematic review to inform the World Health Organization Fungal Priority Pathogens List.
Synthesis in Medical mycology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Sensing the host atmosphere: carbon dioxide regulates virulence and drug response in medically relevant fungi.Medical gas research · 2026Review
- Article
- The AP-1 adaptor complex is required for cell surface modifications and the survival ofInfection and immunity · 2026Article
- Article
- Synergic Effect of Fluconazole and Quinoline Derivatives Combination AgainstMicroorganisms · 2026Article
- An Organoselenium Compound Induces Death inACS omega · 2026Article
- Temporal shifts in adaptive immunity drive HIV-associated cryptococcal IRIS: mechanisms, models, and therapeutic opportunities.NeuroImmune pharmacology and therapeutics · 2026Article
- Article
- Emerging cryptococcosis cases in Himalayan & sub-Himalayan regions of India.New microbes and new infections · 2026Article
- Evaluation of different culture media supporting the growth and melanin production in Cryptococcus.The Indian journal of medical research · 2026Article
- Antifungal-induced DNA dynamics and chitin remodelling across Cryptococcus spp. and the novel broad-spectrum anti-cryptococcal candidate CPTH2.Scientific reports · 2026Article
- Rare case of ulnar cryptococcal osteomyelitis in a 26-year-old immunocompetent patient.Radiology case reports · 2026Article
- Limited genome evolution ofASM case reports · 2026Article
- Roles of Mutation, Ploidy, and Recombination in Adaptive Evolution in Two Divergent Model Yeasts.Genes · 2026Review
- The heat-ramp method to study regulated cell death in a pathogenic yeastbioRxiv : the preprint server for biology · 2026Article
- Cryptococcosis in Colombia: Analysis of Data from Laboratory-Based Surveillance 2017-2024.Journal of fungi (Basel, Switzerland) · 2026Article
- Molecular Epidemiology and Antifungal Susceptibility ofInfection and drug resistance · 2026Article
- Cryptococcal and EBV Meningitis in a Postpartum Woman With HIV Despite ART: A Case Challenging the Limits of Immune Reconstitution.Journal of community hospital internal medicine perspectives · 2026Article
- Multiplanar MRI approach to the differential diagnosis of central nervous system tumors and tumor-like lesions in patients with HIV: what radiologists need to know.Frontiers in medicine · 2026Review
- Fast-tracking fungal detection: a rapid flow cytometric method for the detection of yeasts in blood cultures.Frontiers in microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
Cryptococcosis causes a high burden of disease worldwide. This systematic review summarizes the literature on Cryptococcus neoformans and C. gattii infections to inform the World Health Organization's first Fungal Priority Pathogen List. PubMed and Web of Science were used to identify studies reporting on annual incidence, mortality, morbidity, antifungal resistance, preventability, and distribution/emergence in the past 10 years. Mortality rates due to C. neoformans were 41%-61%. Complications included acute renal impairment, raised intracranial pressure needing shunts, and blindness. There was moderate evidence of reduced susceptibility (MIC range 16-32 mg/l) of C. neoformans to fluconazole, itraconazole, ketoconazole, voriconazole, and amphotericin B. Cryptococcus gattii infections comprised 11%-33% of all cases of invasive cryptococcosis globally. The mortality rates were 10%-23% for central nervous system (CNS) and pulmonary infections, and ∼43% for bloodstream infections. Complications described included neurological sequelae (17%-27% in C. gattii infections) and immune reconstitution inflammatory syndrome. MICs were generally low for amphotericin B (MICs: 0.25-0.5 mg/l), 5-flucytosine (MIC range: 0.5-2 mg/l), itraconazole, posaconazole, and voriconazole (MIC range: 0.06-0.5 mg/l). There is a need for increased surveillance of disease phenotype and outcome, long-term disability, and drug susceptibility to inform robust estimates of disease burden.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.